Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byGilead Sciences
Price$375M
Date2/2011
TermsCash and Stock

General Information

Websitecalistogapharma.com
CategoryBioTech
Phone206-728-4700
Employees
DescriptionCancer & Inflammatory Disease Treatment

Offices

Seattle, USA
2101 4th Avenue, Suite 1960
Seattle, WA, 98121
USA

Funding

Tags

Calistoga Pharmaceuticals

Calistoga Pharmaceuticals is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting the isoforms of the PI3 kinase pathway.

Recent Milestones

Videos

Screenshots

Calistoga Pharmaceuticals screenshot
Above: Calistoga Pharmaceuticals
Uploaded: 10/30/09

Sources

  1. Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million (investors.gilead.com) [edit]
  2. Calistoga Pharmaceuticals, a newly formed drug development company, announces its formation and completion of a $21 million Series A financing (calistogapharma.com) [edit]
  3. SEC (sec.gov) [edit]
  4. Capital Report Index [edit]
  5. Calistoga Pharmaceuticals Raises $40 Million in Series C Financing (calistogapharma.com) [edit]
Edit This Page
Last Edited 2/6/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy